

Psilocybin Advisory Board Meeting Minutes & Chat

February, 27, 2026

1. Opening and Welcoming Statements

The meeting was called to order with opening remarks from:

- Dr. Dominick Zurlo, Director, NM DOH Center for Medical Cannabis & Psilocybin
- Ian Dunn, Board Chair

2. Introductions

- Psilocybin Advisory Board members
- Program staff

3. Review and Adoption of Agenda

The agenda was reviewed. A motion to adopt the agenda was made and seconded. With no objections, the agenda was approved.

4. Program Update

- Two new staff members have been hired for the Psilocybin Program.
- December 2026 is the anticipated date for accepting new patients.

5. Committee Updates

Training and Education Committee – Brenda Burgard

- Document posted on the website; significant input received.
- Second meeting scheduled for next week.
- All interested individuals are welcome to participate.

Equity, Access, and Cultural Considerations Committee – DezBaa

- Committee has held 3–4 meetings to date.
- Focus areas include equity for incarcerated individuals, development of an equity fund, and patient access.
- Awaiting input from Native Nations; working toward engaging a Tribal Liaison.
- Rural considerations and training cost barriers were also discussed.
- Committee anticipates further input and planning.

End of Life Care Committee – Dr. Larry Leeman

- Three meetings held so far.
- Presented “EOL Scopes and Responsibilities” (slides shared).
- Guest educators participated; a list was provided in the chat.

Dosage, Administration, and Clinical Practice Committee – Ian Dunn

- No formal updates at this time.

Patient Qualifications & Safety Committee- Ian Dunn

- Discussion included considerations for clinical support systems.

6. Propagation Rules Update – Chris Peskuski

- Shared a framework (in plain language) outlining sections of the propagation rules; full regulatory language will be developed by the Department.
- Board reviewed and discussed each section.
- A sunset clause aimed at protecting New Mexico residents (page 2) was unanimously supported; members including Chris Woodward, DezBaa, Ian Dunn, and Chris Peskuski shared perspectives.
- Dr. Zurlo amended language during discussion to reflect evolving consensus.

Vote: Propagation Deadline with Definitions Strikeout

- Unanimous consent to adopt.
- Motion carried.

7. Other Business

- Next meeting scheduled for March 20 at 9:00 AM.
- Chris requested guidance on next priorities for the Propagation Committee; Dr. Zurlo noted the need for support reviewing regulation drafts.
- DezBaa requested updates on the Equity Fund and Tribal Liaison.
 - \$630,000 allocated for the Equity Fund
 - \$320,000 allocated for UNM research
 - Awaiting the Governor’s signature

8. Public Comment

Public comment limited to 3 minutes per speaker.

- Jobe: Asked about transportation services under federal government guidelines; inquired about monitoring for “forever chemicals” in water; expressed interest in participating in medical research as a patient.
- Jeremy: Requested elaboration on “full fruiting body.”

9. Adjournment

The meeting was adjourned.

Meeting Chat

[Psilocybin Advisory Board](#) (Site link to future Board and Committee meetings)

Psilocybin Advisory Board

[Dosage, Administration & Clinical Practice](#) - Friday February 27th from 1:00-3:00pm; Ian Dunn, Chair.

[Patient Qualification & Safety](#) – Wednesday March 4th from 9-11am; Ian Dunn, Chair.

[Research and Continuous Improvement](#) – Friday March 6th from 9:00-11:00am; Dan Jennings, Chair.

[Training and Education](#) – Friday March 6th from 1:00-3:00pm; Brenda Burgard, Chair.

[Equity, Access, and Cultural Considerations](#) – Wednesday March 11th from 1:00-2:15pm; DezBaa', Chair.

[Propagation Committee](#) - Wednesday March 11th from 3:00-5:00pm; Chris Peskuski, Chair.

- @ West Mesa Community Center 5500 Glenrio Rd NW, Albuquerque, NM 87105

[Propagation Committee](#) - Wednesday March 18th from 3:00-5:00pm; Chris Peskuski, Chair.

- @ Garrey Carruthers Building (Yucca Room), 1209 Camino Carlos Rey, Santa Fe, NM 87507

[End of Life Care](#) – Friday March 20th from 1:00-3:00pm; Larry Leeman, Chair.

[End of Life Care](#) – Friday April 3rd from 1:00-3:00pm; Larry Leeman, Chair.

Microsoft Virtual Events Powered by Teams

Microsoft Virtual Events Powered by Teams

Contact information:

- Email: Medical.Psilocybin@doh.nm.gov
- Program Website: <https://www.nmhealth.org/about/mcpp/mpp/>
- Advisory Board Website: <https://www.nmhealth.org/about/mcpp/mpp/mpab/>

Medical Psilocybin

EOL Scopes and Responsibilities

• ***Establish Definition and Scope for End-of-Life Criteria***

• ***Therapeutic Team Development***

• ***Inclusion of Family and Caregivers***

• ***Sites of End-of-Life Care***

• ***Education and Workforce Development***

• **Development of Psilocybin Assisted Therapy End-of-Life Care Plans**

•Ongoing Review and Updates

EOL subcommittee guest educators

- Jan 22 Chris Caldwell Founder of EOL Psychedelic Care
-
- February 20 Jenn Clemente Role of Spiritual Care
-
- March 20 Psychedelic Death Doula presentation Danielle Slupesky
-
- April 3 Pharmacological issues for Psilocybin EOL Care James Brown Pharm D
-

Other potential areas: Hospice related issues, Indigenous perspectives, Home care

Early May Blended in-person/virtual meeting to support discussion

Outline: Psilocybin Propagation and Production Framework

I. Purpose and Scope

- Establish a regulated framework for the lawful propagation, production, testing, and preparation of psilocybin products in New Mexico.
- Emphasize public health, safety, consistency, and traceability.
- Minimize duplication by utilizing existing state, county, and municipal licensing and inspection authorities.

II. Authorized Species

- Whole mushroom fruiting bodies shall be harvested for use in this program. Mycelial biomass products are prohibited.

III. Permit Structure

A. Primary Psilocybin Production Permit

- Permits Issued by the Department
- Required for production, which includes:
 - Cultivation
 - Harvesting
 - Processing (i.e., homogenizing)
 - Packaging
- Applying persons can apply for one or any aspects of the permit[G-1] [DZ2]
- Demonstrate psilocybin containing mushrooms/products are kept in a secure location; i.e.
 - Double locks
 - Video surveillance
 - Alarm system
 - Commercial grade locks
 - Keypad entry

[G-1]Tighter Language: Applicants may apply for authorization to conduct one or more production activities, including cultivation, harvesting, processing, and packaging.

[DZ2]Remember, this is only an outline. The language in the rules themselves will be more specific and tighter.

B. Business, Facility, and Occupancy Compliance

- Proof of ownership of the land/facility or written approval from the owner (i.e., lease specifying use to include psilocybin cultivation/production)
- Business License in the State of New Mexico
- Proof of Registration with NM Secretary of State
- Registration with NM Tax and Revenue
- Local Building and Safety Authorities
 - Certificate of Occupancy
 - Fire code compliance
 - Electrical and HVAC inspection
- *No new psilocybin-specific building standards unless explicitly necessary.

C. Zoning and Municipal Permits

- Must be within the geographical boundaries of New Mexico
- City and County Planning / Zoning Departments
 - Land use approval
 - Conditional use permits where applicable – i.e., City of Albuquerque raw food permit
- Food safety training certification for employees
- Note: Local governments retain zoning authority consistent with existing agricultural, ~~or~~ light industrial, and other classifications.

D. Agricultural:

- New Mexico Department of Agriculture (NMDA)
 - Utilize Pest and contamination mitigation guidance
- Production is treated analogously to controlled-environment agriculture

IV. Cultivation Standards

A. Growth Medium

- Growth medium is not restricted [G-1] [DZ2]
 - All substrates and inputs must be:
 - ♣ Documented
 - ♣ Tracked
 - ♣ Fully disclosed on final product labeling

B. Environmental Controls

- Indoor or controlled-environment cultivation required
- No pesticides utilized [G-3]
- Other substances determined harmful by the Department

[G-1] Tighter Language: Growth medium inputs must be safe, documented, and not contain substances prohibited by the Department.

[DZ2] See previous comment.

[G-3] Amendment:

The use of pesticides, fungicides, or other chemical agents is prohibited unless:

- (1) The substance is registered for use on edible fungi or food crops under applicable federal or state law;
- (2) The producer maintains documentation of application and adherence to label requirements; and
- (3) No detectable pesticide residues exceed action levels established by the Department based on toxicological and public health standards.

This is Mary Curry, PhD and I am muted. If I have a question, do I post it here?

mary curry,PhD

This is Mary Curry, PhD and I am muted. If I have a question, do I post it here?

Yes, you can post it here in the chat.

V. Harvesting, Processing, and Homogenization

A. Batch Definition

- A "batch" is defined as harvested and homogenized under uniform conditions utilizing best practices at no more than 1 kilogram after drying over a 4-week period.
- Batches must be fully homogenized prior to testing.

B. Homogenization Requirements

- Physical homogenization is required to ensure consistent potency across the batch.
- Purpose:
 - Accurate potency testing
 - Reduction of dose variability

this is for harvesting the fruiting bodies which have been harvested over a 4-week period.

this is for fruiting bodies from the same inoculation which have been harvested over a 4-week period.

mary curry,PhD

This is Mary Curry, PhD and I am muted. If I have a question, do I post it here?

Hi Mary, also the Advisory Board will open up the meeting to public comment/questions at the end of their agenda. You can raise your hand at that point or submit comment in chat.

- **A. Testing Authority**

- Testing is performed by Department permitted laboratories
- Requirements for laboratories to be permitted
 - ♣ Cannabis testing laboratories which have been approved (submit SOP/IDCs and process for extraction) and similar pathway for those who are not a cannabis testing laboratory:
 - ISO/IEC 17025 or NELAC/TNI (<https://nelac-institute.org/index.php>) accredited labs; or,
 - Labs approved or overseen by the Department i.e., State Lab Division
- Ensure proficiency and verification testing annually
- The Department can require samples to be conducted by additional labs for validation purposes

The NELAC Institute (TNI)

So if a cultivator grows (for example) 2 different strains and uses 2 different substrates, they would need to send in 4 samples for testing?

- **B. Required Testing Panels**

- Testing occurs once the batch is homogenized
- Cultivators must submit a sample of each homogenized batch and may be between 2-5 grams as required by the testing laboratory sampling procedures
- The department can stagger the implementation of testing as laboratories are permitted and are able to provide validation of testing.
- Product will need to be re-tested one year after the initial test date
- The Department can require additional tests if there are complaints, concerns, or at random;

- No cultivation or processing facility will be asked to test more than 4 times a year with regard to the random testing; except if there are contaminants or false statements made by the organization/facility or on the labels
- Potency Testing
 - Psilocin
 - Psilocybin
 - ♣ Baeocystin, norbaeocystin and aeruginascin
- Contaminant Testing
 - Microbial contamination (examples)
 - ♣ E. coli
 - ♣ Salmonella
 - Heavy metals (this is an example)
 - ♣ The limits for heavy metal testing are:
 - Arsenic (As) above .2 µg/g.
 - Cadmium (Cd) above .2 µg/g.
 - Lead (Pb) above .5 µg/g.
 - Mercury (Hg) above .1 µg/g.[G-1] [DZ2]
 - Pesticides/fungicides
 - Synthetic tryptamine screening - upon request of the department in the event there is suspicion of it having been added.

[G-1]Tighter Language: "Heavy metal limits shall be consistent with Department-established thresholds based on existing cannabis or food safety standards."

[DZ2]Will be tighter in the regulations themselves.

any rough estimate on what the cost will be for each batch analyzed?

Thats incredible

C. Batch Release

- Only batches that pass all required testing may be released for use

VII. Food Preparation and Product Handling

A. Applicability

- Any conversion of raw material into ingestible or prepared products subject to food safety oversight.
- Environmental Health / Food Safety Divisions
 - Food safety and handling training/certification
- No exemption from standard food safety requirements.

VIII. Labeling, Packaging, and Traceability (tracking)

A. Packaging

- Sealed
- Label
- Ensure the facilitator provides this information for the label and the product information document for the patient.

B. Required Label Elements

- The label must be printed or affixed on the product package and must include:
- Contain all required information in a legible font at least eight points.
- Be in English, though it may also be provided in other languages.
- Be unobstructed and clearly visible.
- The producer's business name and permit number.
- The type of product (ie, homogenized fungi)
- The species and cultivar name of the fungi
- The net quantity of contents using the metric system of measurement
- The potency of psilocybin analytes contained in the product, expressed in milligrams, and calculated using laboratory test results.
- Total Potential Psilocyn (report both or one of TPP or TPE)
- Total Psilocybin Equivalent
- A logo designed and provided by the department that notifies a reasonable person that the product contains psilocybin that is no smaller than 1/2 inch by 1/2 inch.
- A unique identification number of the product lot, and the state traceability system number or identifier associated with the product;-
- The expiration date; and,
- The statement: "The risks, benefits, drug interactions, and effects of psilocybin are not fully understood. Individual results may vary."
- The statement "Keep out of the reach of children."

- The statement "Do not drive a motor vehicle or operate machinery while under the use of psilocybin."

Dang, I was looking forward to wall papering my house with CVS length psilocybin labels

Do you all monater for psa?

C. Product Information Document

- A product information document must be available that lists the following information in English on a printed or electronic document in 12-point font or larger:
 -
 - All of the requirements for the product label;
 - A statement regarding the number of years the business has been established in New Mexico and a statement declaring the state and country of residency, including length of time, of their primary investors;[G-1]
 -
 - Results of all laboratory tests conducted on the homogenized batch;
 -
 - Date of homogenization;
 - The type and composition of the growth medium used, including type of grain, soil, compost, pesticides, and other inputs;
 - Date of manufacture or processing of the final product;
 - List of all active and inactive ingredients in descending order of predominance by weight or volume;
 - Growth medium used;
 - List of potential major food allergens which might be contained in the product or in the growth medium;
 - Identify the intended use and directions for use; and,
 - A description of how the product should be stored;
 - The following statement: "This product is not approved by the FDA to treat, cure, or prevent any disease. FDA has not evaluated this product for safety, effectiveness, and quality. There may be long term adverse health effects from consumption of psilocybin, including additional risks for women who are or may become pregnant or are breastfeeding."
 - The New Mexico poison and drug information center phone number;

[G-1] This is an economic regulation, not a medical regulation, thus it is outside of our jurisdiction to make a recommendation on.

Forever chemicals in water. Sorry i got here late.

What about suicide crisis hotline? 988

D. Traceability (tracking)

- Utilize online tracking system as required by the Department
- End-to-end batch tracking from cultivation through final product
 - Steps for grow, harvest, processing, testing, transport/sale.
- Records retained for a defined regulatory period (5 years)

IX. Compliance

- Compliance authority:
 - The Department
 - NMDA for applicable permits
 - Local building and health departments/inspectors for local permits
- Clear corrective action pathways prior to license suspension or revocation.

X. Transportation needs to be done in safe and secure way.

Ensure can meet with others (ie, contractors) or allow for pick-up so long as there is a chain of custody form (ie, manifest).

brb

XI. Future Expansion and Review

- Framework designed to be scalable.
- Periodic review for:
 - Scientific developments
 - Public health data

- o Operational performance

Are there specific regulations as a clinician/facilitator?

For transportation?

back

To be considered by the Board - Initial Ownership/sunset clause proposal from Committee:

If the applicant is a corporation, limited liability company, partnership, association, trust, or other legal or commercial entity:

a. Ownership Requirements More than 51% of the ownership interest in the applicant must be held by one or more individuals who have been residents of the State of New Mexico for a minimum of 36 months immediately preceding the date of the application; and

b. Control Requirements The individuals described in Subsection (a) must possess actual authority to direct the management, policies, and operations of the applicant, whether through voting rights, management authority, contractual rights, or other indicia of control, as determined by the New Mexico Department of Health.

Notwithstanding any other provision of law, and until January 1st, 2029, an applicant for a license subject to this measure must demonstrate compliance with the residency and ownership requirements set forth in this measure.[G-1]

[G-1]This is an economic regulation, not a public health regulation and thus is outside of our jurisdiction

How do i register for testing, as a patent?

job levesque (Guest)

How do i register for testing, as a patient?

Patent or Patient?

job levesque

How do i register for testing, as a patient?

The regulations for patient registration have not yet been created. The goal is to have processes in place and to have the first patients seen in December of 2026.

Wouldnt creating a transportation service resolve transportation issues?

Resolve

I agree that cross-agency and governing entities is necessary in making recommendations and oversight. Is there a committee that brings all responsible and involved together? The old one hand washes the other and both hands wash the face.

job levesque

Wouldnt creating a transportation service resolve transportation issues?

Transportation services would still need to meet the same requirements.

mary curry,PhD

I agree that cross-agency and governing entities is necessary in making recommendations and oversight. Is there a committee that brings all responsible and involved together? The old one hand washes the other and both hands wash the face.

Other agencies have been invited and several have been attending the various and appropriate committee meetings.

That's not exactly my question. Is there a formal cross-agency/entity committee, with required representation.

A. Compliance with applicable laws: A permittee [CW1] shall comply with all applicable state, tribal, and local laws, regulations, and ordinances, including requirements concerning agriculture, environmental health, building and occupancy, fire safety, zoning, and worker safety.

B. Dual ownership prohibited: A person who holds an ownership interest in a permittee shall not hold an ownership interest in any other permittee.

C. Permits non-transferable: [CW2] A permit shall not be transferred by assignment or otherwise to another person. A permit that is transferred to another person shall be invalid. An applicant or permittee shall not convey actual control of the applicant or permittee to another person through the use of a management, consulting, or intellectual property agreement, or by any other means.

D. Nominee, straw, and proxy ownership prohibited: A person shall not apply for or hold a permit [CW3] if any ownership interest in the permit [CW4] is nominal or without the benefits and risks of genuine ownership or control.

E. Record of financial interests: Permittees shall create and maintain complete lists of all individuals and legal entities that hold a financial interest in the permittee or the operations of the permittee, including contact information for each individual or entity and a description of their financial interest. Applicants and permittees shall provide the information required by this section to the department within 15 calendar days of the department's written request for such information. If a legal entity holds a financial interest in the permittee or the permittee's operations within the Medical Psilocybin Program, the following individuals within the legal entity shall be deemed to also hold a financial interest:

(a) For limited partnerships, each general partner in the limited partnership;

(b) For limited liability companies, each manager and managing member of the limited liability company;

(c) For for-profit corporations, each principal officer of the corporation; and

(d) For non-profit entities, each principal officer of the entity.

Is anyone at DOH tracking the "Great American Recovery Initiative" and how that may impact what is going on with this entire program?

mary curry,PhD

That's not exactly my question. Is there a formal cross-agency/entity committee, with required representation.

They are not required, but have been invited.

Just want to say that I think this is excellent work by this group and I really appreciate all the thoughtfulness and perspectives that went into it. Congrats.

I'm interested in the treatment guideline and regulations, how do I get involved in that aspect?

3/20 am

[Dosage, Administration & Clinical Practice](#) - Friday February 27th from 1:00-3:00pm; Ian Dunn, Chair.

[Patient Qualification & Safety](#) – Wednesday March 4th from 9-11am; Ian Dunn, Chair.

[Research and Continuous Improvement](#) – Friday March 6th from 9:00-11:00am; Dan Jennings, Chair.

[Training and Education](#) – Friday March 6th from 1:00-3:00pm; Brenda Burgard, Chair.

[Equity, Access, and Cultural Considerations](#) – Wednesday March 11th from 1:00-2:15pm; DezBaa', Chair.

[Propagation Committee](#) - Wednesday March 11th from 3:00-5:00pm; Chris Peskuski, Chair.

- @ West Mesa Community Center 5500 Glenrio Rd NW, Albuquerque, NM 87105

[Propagation Committee](#) - Wednesday March 18th from 3:00-5:00pm; Chris Peskuski, Chair.

- @ Garrey Carruthers Building (Yucca Room), 1209 Camino Carlos Rey, Santa Fe, NM 87507

[End of Life Care](#) – Friday March 20th from 1:00-3:00pm; Larry Leeman, Chair.

[End of Life Care](#) – Friday April 3rd from 1:00-3:00pm; Larry Leeman, Chair.

Microsoft Virtual Events Powered by Teams

Microsoft Virtual Events Powered by Teams

Contact information:

- Email: Medical.Psilocybin@doh.nm.gov
- Program Website: <https://www.nmhealth.org/about/mcpp/mpp/>
- Advisory Board Website: <https://www.nmhealth.org/about/mcpp/mpp/mpab/>

Medical Psilocybin

Microsoft Virtual Events Powered by Teams


Microsoft Virtual Events Powered by Teams

not that I think there is necessarily a solution, but has there been any discussion around breeding and creating more potent strains and what will happen with that? As we have seen in the cannabis community, the results of that haven't been overwhelmingly positive


obviously this is a different substance used in a different way, but as more programs come online in states, I wonder what will be the results of that and is it worth considering now?

How to raise your hand to speak:

- If on a computer – click on the “hand” icon near the top of the Teams window (it says “Raise” under the icon)



- If on the Teams app on a phone, please press the ellipses (three dots) in the menu and then the "hand" icon will appear, and you can select it



- If you are joining through voice only on a phone, press *5 to raise or lower your hand

How to Unmute:

- Once your name is called, you will be able to unmute:
- To unmute/mute on Teams on a Computer or on the Teams Phone App click on the microphone icon:



- On a computer it is in the upper right area of the Teams window.
- On a phone it is usually in the lower left of the Teams App, however, different models of phone (Apple, Android, etc...) may have the mute/unmute icon in a different location:
- Telephone: voice only - press *6 to unmute/mute

Eileen Brewer

not that I think there is necessarily a solution, but has there been any discussion around breeding and creating more potent strains and what will happen with that? As we have seen in the cannabis community, the results of that haven't been overwhelmingly positive

the discussions have not occurred at this point, but this is a part of testing and something which would be monitored.

How to submit written public comments:

- Please send written public comment to the program email at: medical.psilocybin@doh.nm.gov and include the committee's name in the subject line.
- If referencing documents from other sources/websites:
 - Do not include the document, only a working - accessible hyperlink;
 - Documents must be sent with context provided (i.e. do not simply send a research article);
- The comment must relate to the topics discussed in the meeting.
- Documents are limited to no more than 3 pages (letter size) in length and must be in 10-point font or larger.
- Please remember to include your full, legal name and any organizational affiliations you may be representing (if any) on the documents.
- To be included, please send your comment by 5:00 PM the day after the meeting.

Congratulations Chris and Everyone.

Friday 10:57 AM Meeting ended: 2h 12m 51s Medical Psilocybin Advisory Board Meeting
2/27/26Friday, February 27, 2026 9:00 AM - 11:00 AMView recap3ContentAttendanceEOLLSlides2-
27Advisory Board.pptx+11h 51m 32s